J. Montegaard

发表

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

A. LaCasce, S. Tyekucheva, M. Davids, 2021, The Lancet. Oncology.

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

S. Tyekucheva, P. Armand, M. Davids, 2020, Leukemia.

Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome.

S. Tyekucheva, Catherine J. Wu, M. Davids, 2021, Blood.

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

S. Tyekucheva, M. Davids, D. Fisher, 2020 .

Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome

A. LaCasce, S. Tyekucheva, M. Davids, 2023, Hematological Oncology.

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

A. LaCasce, S. Tyekucheva, P. Armand, 2019, Blood.

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

A. Alencar, A. LaCasce, S. Tyekucheva, 2021, Blood.

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

A. Alencar, S. Tyekucheva, M. Davids, 2022, Blood.